We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App





Quidel Showcases Comprehensive Suite of COVID-19 Testing Solutions at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 21 Jun 2021
Print article
Image: Sofia Q Fluorescent Immunoassay Analyzer (Photo courtesy of Quidel Corporation)
Image: Sofia Q Fluorescent Immunoassay Analyzer (Photo courtesy of Quidel Corporation)
Quidel Corporation (San Diego, CA, USA) showcased its comprehensive suite of COVID-19 testing solutions at MEDLAB Middle East 2021 that took place in Dubai from 21-24 June.

Quidel introduced its new Sofia Q Fluorescent Immunoassay Analyzer, a powerful clinical diagnostic device in a very compact size, to be used with its Sofia SARS Antigen FIA Test Cassettes to diagnose COVID-19. Sofia Q uses advanced fluorescence detection with an ultraviolet LED energy source and collects hundreds of data points on the test strip contained inside the Test Cassette. Quidel recently received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition to the Sofia and Sofia 2 line of Fluorescent Immunoassay Analyzers (FIA).

In addition to the Sofia Q, Quidel also exhibited other rapid diagnostic instrumented systems, including Sofia 2, and Sofia. Also on display were Quidel’s Sofia assays for rapid antigen COVID-19 diagnosis, including Sofia 2 SARS Antigen FIA and Sofia 2 Flu + SARS Antigen FIA, currently under EUA by the FDA. At MEDLAB Middle East 2021, Quidel also highlighted its other FDA-cleared and CLIA-waived tests, including Influenza A and B, Respiratory Syncytial Virus (RSV), Group A Strep, and a 15-minute finger-stick whole blood test for Lyme Disease.

Related Links:
Quidel Corporation

New
Gold Supplier
Body Fluid Application
CellaVision Body Fluid Application
New
Silver Supplier
Urea Breath Test
13C-Urea Breath Test
New
Zika Virus ELISA Test
RecombiLISA Zika IgM ELISA CE
New
Gold Supplier
HAI Assay Quality Control
Amplichek II

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.